Cullinan Therapeutics, Inc.
CGEM
$12.76
-$0.38-2.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -0.20% | 27.76% | -44.44% | -1.79% | -17.47% |
| Total Depreciation and Amortization | 0.00% | 2.60% | 1.32% | -1.30% | 1.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.31% | -0.88% | 15.83% | 15.35% | 35.98% |
| Change in Net Operating Assets | 10.80% | 32.40% | 333.58% | -137.19% | 161.73% |
| Cash from Operations | -3.34% | 35.99% | -33.49% | -17.83% | -7.28% |
| Capital Expenditure | 71.05% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -66.78% | 26.27% | 45.09% | 130.55% | -19.69% |
| Cash from Investing | -66.77% | 26.20% | 45.09% | 130.55% | -19.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -20.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -- | -100.00% | -- | -- | 19.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -149.17% | 895.70% | 39.61% | 66.72% | -47.50% |